Post a Comment Print Share on Facebook
Featured UE Pedro Sánchez PP Estados Unidos Sumar

RELEASE: AmacaThera doses first-in-human study to evaluate, AMT-143

(Information sent by the signatory company).

- 3 reads.

RELEASE: AmacaThera doses first-in-human study to evaluate, AMT-143

(Information sent by the signatory company)

- AmacaThera doses first-in-human study to evaluate, AMT-143, for non-opioid treatment of postoperative pain

TORONTO, May 15, 2024 /PRNewswire/ -- AmacaThera Inc, a clinical-stage biotechnology company specializing in the development of advanced sustained-release hydrogel formulations, has dosed its first human subject with AMT-143, the lead active of the company in the treatment of acute pain without opioids.

AMT-143 is a slow-release, non-opioid local anesthetic that would leverage the AmacaGel platform to provide long-acting postoperative pain relief and is the first therapeutic product formulated to be delivered via AmacaGel, the company's proprietary technology platform.

Previously, the company had tested the AmacaGel platform without any active pharmaceutical agents. This trial will test the platform combined with a known anesthetic. The study will evaluate the tolerability, safety, pharmacokinetics and clinical activity of the AmacaGel platform with a known compound that has a long history of safety and efficacy.

If approved, AMT-143 could one day be used to reduce postoperative pain without the need for opioids. AMT-143 would be applied to the incision site at the time of surgery to control local pain.

"A successful outcome will be data demonstrating the safety of our asset and release kinetics showing sustained release for longer than competing products," said Dr. Mike Cooke, CEO and co-founder of AmacaThera. "There is a real need for products that provide longer-lasting relief than those currently available on the market."

Dr. Molly Shoichet is the company's chief scientific officer and co-founder of AmacaThera. The original technology was developed in her laboratory at the University of Toronto. "My lab has demonstrated AmacaGel's compatibility with a wide range of therapies, from cells to biologics," Shoichet explained. "With this study, we aim to provide human data on our technology that will help advance AMT-143 to the clinic. At the same time, we are developing the platform technology so it can be leveraged for other local release therapies."

About AmacaThera

AmacaThera is a clinical-stage biotechnology company specializing in the development of advanced sustained-release hydrogel formulations to solve key therapeutic delivery challenges with both proprietary and off-patent payloads. AmacaThera is focused on developing an internal portfolio of oncology and pain assets; and partner to solve key delivery challenges with advanced proprietary therapeutic modalities.

AmacaThera's platform technology, AmacaGel, is a rapidly gelling physical hydrogel blend of two well-established medical-grade polymers. It has been designed to liquefy under the shear force delivered with a conventional syringe, quickly forming a deposit at the injection site as it warms to body temperature. AMT-143, the platform's lead asset, is a slow-release, non-opioid local anesthetic that leverages the AmacaGel platform to provide long-acting postoperative pain relief.

For more information, visit www.amacathera.ca

Media Contact: Abhaya Khulbe, Investor Relations, info@amacathera.ca

Logo - https://mma.prnewswire.com/media/2412859...

View original content: https://www.prnewswire.com/news-releases/amacathera-dosifica-el-primer-estudio-en-humanos-para-evaluar-amt-143-302146193.html